

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number
WO 2005/067903 A1

(51) International Patent Classification⁷: **A61K 31/045**,
31/397, A61P 3/06

(21) International Application Number:
PCT/IN2005/000025

(22) International Filing Date: 19 January 2005 (19.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
103/DEL/2004 20 January 2004 (20.01.2004) IN

(71) Applicant (for all designated States except US):
PANACEA BOITEC LTD. [IN/IN]; B-1 Extn., A-27,
Mohan Co-Operative Industrial Estate, Mathura Road,
New Delhi 110 044 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JAIN, Rajesh**
[IN/IN]; Panacea Biotec Ltd., B-1 Extn./A-27, Mohan
Co-Operative, Industrial Estate, Mathura Road, New
Delhi 110 044 (IN). **JINDAL, Kour, Chand** [IN/IN];
Panacea Biotec Ltd., B-1 Extn., A-27, Mohan Co-Opera-
tive Industrial Estate, Mathura Road, New Delhi 110 044
(IN). **SINGH, Sukhjeet** [IN/IN]; Panacea Biotec Ltd.,
B-1 Extn., A-27, Mohan Co-Operative Industrial Estate,
Mathura Road, New Delhi 110 044 (IN).

(74) Agent: **GUPTA, Bhartee**; Panacea Biotec Ltd., B-1
Extn./A-27, Mohan Co-operative Industrial Estate,
Mathura Road, New Delhi 110 044 (IN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING HIGHER PRIMARY ALCOHOLS AND EZETIMIBE AND
PROCESS OF PREPARATION THEREOF

(57) Abstract: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and ezetimibe, its salts, analogs or derivatives thereof optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.

WO 2005/067903 A1

PHARMACEUTICAL COMPOSITIONS COMPRISING HIGHER PRIMARY ALCOHOLS AND EZETIMIBE
AND PROCESS OF PREPARATION THEREOF**Field of the invention**

The present invention relates to novel pharmaceutical compositions comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one
5 another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and ezetimibe, its salts, analogs or derivatives thereof optionally with pharmaceutically acceptable excipients, and process of preparation of such composition. Also described are method of treatment and use of
10 such composition thereof for reducing abnormal lipid parameters associated with hyperlipidemia. Particularly, the present invention relates to compositions and method for lowering total cholesterol and triglycerides (TGs) level or elevating high density lipoprotein cholesterol (HDL-C) level in blood of a mammal.

BACKGROUND OF THE INVENTION

15 Elevated serum cholesterol levels (>200 mg/dl) have been indicated as a major risk factor for heart disease, the leading cause of death worldwide. Atherosclerotic vascular diseases, especially coronary heart disease (CHD), are the major cause of morbidity and mortality in middle age and elderly people worldwide (Pyorala et al., 1994; Sans et al., 1997). Thus, primary and secondary prevention of morbidity and death from CHD
20 represents a major healthcare problem.

However, the use of currently available statins and fibrates should be used with caution in special patient population with increased susceptibility to drug-related adverse effects and frequent consumption of several concomitant medications, such as the elderly, patients with active hepatic diseases, etc. Furthermore, these lipid-lowering
25 drugs are associated with adverse effects such as gastrointestinal disturbances, increases in serum transaminases and creatinine kinase, myopathies, headache, cholelithiasis, impairment of fertility, and diminished libido. Due to the fact that cholesterol-lowering drugs must be administered on a long-term basis, there is still need of new effective and well-tolerated hypocholesterolemic agents.

The regulation of whole body cholesterol homeostasis in humans and animals involve the regulation of dietary cholesterol and modulation of cholesterol biosynthesis, bile acid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteins. The liver is the major organ responsible for cholesterol biosynthesis and catabolism, and for this reason it is a prime determinant of plasma cholesterol levels. The liver is the site of synthesis and secretion of very low density lipoproteins (VLDL) which are subsequently metabolized to low density lipoproteins (LDL) in the circulation. LDL is the predominant cholesterol-carrying lipoproteins in the plasma and an increase in their concentration is correlated with increased atherosclerosis.

Plant derived long-chain aliphatic alcohols have also been documented to reduce serum cholesterol levels in experimental models, and in type II hypercholesterolemic patients. Mixture of higher primary aliphatic alcohols has been employed in the treatment of elevated serum cholesterol levels. In the past few years such mixtures have shown much promise as reported in a number of published human clinical trials. The mechanism of action of such mixtures is not known, but various studies revealed that such mixtures inhibit cholesterol biosynthesis, increase the number of LDL-C receptors thereby decreases serum TC, LDL-C and increase HDL levels (Menendez et al., 1994).

US Patent 5,856,316 discloses a process for obtaining mixture of higher primary aliphatic alcohols from sugarcane wax and their utilization in the treatment of hypercholesterolemia. Such mixture from sugarcane wax comprise a mixture of aliphatic alcohols from 24 to 34 carbon atoms and they were effective hypocholesterolemic agents administered in daily doses from 1 to 100 mg.

Ezetimibe selectively inhibits the intestinal absorption of cholesterol and related phytosterols leading to a reduction of hepatic cholesterol stores and increase in clearance of cholesterol from blood. When intestinal cholesterol absorption is reduced, by whatever means, less cholesterol is delivered to the liver. The consequence of this action is decreased hepatic lipoprotein (VLDL) production and an increase in the hepatic clearance of plasma cholesterol, mostly as LDL. Thus, the net effect of inhibiting intestinal cholesterol absorption is a decrease in plasma cholesterol levels.

A few azetidinones have been reported as being useful in lowering cholesterol and/or in inhibiting the formation of cholesterol-containing lesions in mammalian arterial walls. US Patent No. 4,983,597 discloses N-sulfonyl-2-azetidinones as antihypercholesterolemic agents.

- 5 The US Patent No. 6,498,156 discloses diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use as hypolipidemics.

US Patent No. RE37721 discloses hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents. Ram et al (1990) disclose ethyl 4-(2-oxoazetidin-4-yl)phenxy-alkanoates as hypolipidemic agents.

10

European Publication No. 264,231 discloses 1-substituted-4-phenyl-3-(2-oxoalkylidene)-2-azetidinones as blood platelet aggregation inhibitors.

- European Publication Nos. 199,630 and 337,549 disclose elastase inhibitory substituted azetidinones said to be useful in treating inflammatory conditions resulting in tissue destruction, which are associated with various disease states, e.g. atherosclerosis.
- 15

US Patent No. 5,846,966 discloses combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors.

- The US Publication No. 20030232796 relates to nanoparticulate compositions comprising particles of at least one mixture of concentrated n-alkyl alcohols or a salt thereof, wherein the particles have an effective average particle size of less than about 2000nm; and at least one surface stabilizer preferably selected from the group consisting of an anionic surface stabilizer, a cationic surface stabilizer, a zwitterionic surface stabilizer, and an ionic surface stabilizer. The compositions described additionally comprise one or more active agents resulted from the group comprising of cholesterol lowering agents such as ezetimibe; although no disclosure has been made by way of examples for preparing such composition. However such nanoparticulate compositions are difficult to formulate and the particle size of the active agent becomes very crucial for proper bioavailability and primarily becomes a limiting aspect.
- 20
- 25

The PCT Publication No. WO 0390547 relates to compositions comprising a waxy acid component consisting of at least a waxy acid with 23 to 50 carbon atoms and/or derivatives thereof and 0 to 99.99% by weight of at least a component with serum cholesterol level effecting properties and 0 to 20% by weight of at least a
5 pharmaceutically acceptable formulation aid.

The mechanism of action of mixture of higher primary aliphatic alcohols is not known, but *in vitro* studies revealed that the mixture of higher primary aliphatic alcohols inhibit cholesterol biosynthesis at a step located in between acetate consumption and
10 mevalonate production. In addition, *in vitro studies* also showed that such mixtures increase the number of LDL-C receptors (Menendez et al., 1994). This accounts for the ability of the mixture of higher primary aliphatic alcohols not only to decrease total cholesterol, but also to decrease LDL serum levels and increase HDL levels. *In vivo* studies in correlation with *in vitro* studies demonstrated that such mixtures inhibited TC
15 and LDL-C induced by atherogenic diet suggesting possible inhibition of cholesterol biosynthesis (Menendez et al., 1996). In addition, administration of such mixtures to diabetic patients significantly reduced TC and LDL-C levels in the blood (Omayda Torres et al., 1995).

Ezetimibe, a diphenylazetidinone derivative that localizes and appears to act at the
20 brush border membrane of the small intestine and selectively inhibits the intestinal absorption of cholesterol and related phytosterols leading to a decrease in the delivery of intestinal cholesterol to the liver. It does not inhibit cholesterol synthesis in the liver. This causes a reduction of hepatic cholesterol stores and increase in clearance of cholesterol from blood. It reduces TC, LDL-C, Apo B, and TG, and increases HDL-C
25 in patients with hypercholesterolemia.

It can be seen from the scientific literature that there is still a need for development of new drugs or combinations of existing antihyperlipidemic agents with possible additive, potentiating, or synergistic action and a method of administration which would provide a balanced lipid alteration i.e. reductions in TC, LDL-C, TGs, and
30 apolipoprotein a (Lp(a)) as well as increases in HDL-C, with an acceptable safety

profile, especially with regards to liver toxicity and effects on glucose metabolism and uric acid levels in hyperlipidemic patients; and which are cost-effective and easier to formulate; but are still beneficial.

Summary of the invention

5 It is an objective of the present invention to provide novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to 99.9% by weight of the composition; at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition, and ezetimibe, its
10 salts, analogs or derivatives thereof substantially devoid of any waxy acid, optionally with pharmaceutically acceptable excipients from 0 to 99.9% by weight of the composition.

It is an objective of the present invention to provide a process for preparing such
15 composition which comprises of the following steps:

- i) isolating the wax,
- ii) subjecting the wax to extraction with a liquid organic extractant in which primary aliphatic alcohols and other organic components are soluble,
- iii) recovering said soluble mixture from said extractant,
- 20 iv) purifying the extract by repeated washing and crystallization,
- v) drying the extract and making it into a powder form,
- vi) adding ezetimibe, its salts, analogs or derivatives,
- vii) optionally adding pharmaceutically acceptable excipients and making it into a suitable dosage form.

25

It is yet another objective of the present invention to provide a method of reducing serum cholesterol level, and treating hyperlipidemia, which comprises administering a composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to 99.9% by weight of the composition; at least one another
30 organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition,

and ezetimibe, its salts, analogs or derivatives thereof, substantially devoid of any waxy acid, optionally with pharmaceutically acceptable excipients from 0 to 99.9% by weight of the composition.

- 5 The compositions of the present invention have preferably a synergistic effect for reducing serum cholesterol level in mammals.

Detailed description of the invention

The present invention relates to novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to
10 99.9% by weight of the composition; at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition, and ezetimibe, its salts, analogs or derivatives thereof.

- 15 The compositions of the present invention are substantially devoid of any waxy acid, optionally with pharmaceutically acceptable excipients from 0 to 99.9% by weight of the composition.

The mixture of higher primary aliphatic alcohols in the present invention are selected
20 from but not limited to a group comprising 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, 1-nonacosanol, 1-tetratriacontanol, 1-triacontanol, 1-hexacontanol, eicosanol, 1-hexacosanol, 1-tetracosanol, 1-dotriacontanol, 1-tetracontanol, and the like. Preferably the mixture of higher primary aliphatic alcohols comprises 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, and 1-
25 triacontanol.

In a further embodiment, the present invention provides a composition, wherein the mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms comprising 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, and 1-triacontanol are
30 present as at least 40% by weight of the composition.

In a further embodiment, the present invention provides a composition, wherein the ratio of the mixture of higher primary aliphatic alcohols and ezetimibe, its salts, analogs or derivatives thereof is from 20:1 to 1:20.

- 5 In another embodiment of the present invention, the mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms and the other organic component(s) selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds comprises of the following:

10	1-tetracosanol	0.0-2.0%
	1-hexacosanol	0.2-2.0%
	1-heptacosanol	0.0-1.0%
	1-octacosanol	30.0-40.0%
	1-triacontanol	6.0-9.5%
15	Resins and pigments	5.0-10.0%
	Hydrocarbons	1.0-10.0%
	Esters	1.0-10.0%
	Ketones and Aldehydes	1.0-10.0%
	Phenolic compounds	0.0-5.0%

20

In a still further embodiment of the present invention, the mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms and the other organic component(s) selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, phytosterols, and phenolic compounds comprises of the following:

25

	1-tetracosanol	0.0-2.0%
	1-hexacosanol	0.2-2.0%
	1-heptacosanol	0.0-1.0%
	1-octacosanol	30.0-40.0%
	1-triacontanol	6.0-9.5%
30	Phytosterols	0.1-1.0%
	Resins and pigments	5.0-10.0%
	Hydrocarbons	1.0-10.0%

Esters	1.0-10.0%
Ketones and Aldehydes	1.0-10.0%
Phenolic compounds	0.0-5.0%

The mixture of high-molecular weight aliphatic alcohols of the present invention occur naturally in wax form and are characterized by fatty alcohol chains ranging from 20 to 39 carbon atoms in length. The major components of such mixture are the aliphatic alcohols 1-octacosanol and 1-triacontanol, and the component includes 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, 1-nonacosanol, 1-tetratriacontanol, 1-triacontanol, 1-hexacontanol, eicosanol, 1-hexacosanol, 1-tetracosanol, 1-dotriacontanol, 1-tetracontanol, and the like; and other organic components such as resins and pigments, hydrocarbons, esters, ketones and aldehydes, phytosterols, phenolic compounds, and the like. Such mixture of high-molecular weight aliphatic alcohols and other organic components of the present invention are preferably isolated from a number of different sources, including sugar cane wax, beeswax, and rice bran wax, more preferably sugar cane wax. It should be understood, however, that the invention is not limited in this regard and that such mixture of high-molecular weight aliphatic alcohols commonly available from other naturally occurring and synthetic sources may be utilized.

In an embodiment, the present invention employs ezetimibe or a compound other than ezetimibe itself that the body metabolizes into ezetimibe, thus producing the same effect as described herein. The other compounds include N-sulfonyl-2-azetidinones, diphenylazetidinone derivatives, hydroxy-substituted azetidinone compounds, ethyl 4-(2-oxoazetidin-4-yl) phenxy-alkanoates, 1-substituted-4-phenyl-3-(2-oxo-alkylidene)-2-azetidinones or the like, and their analogs or salts thereof. Each such compound will be collectively referred to herein by "ezetimibe."

The mixture of higher primary aliphatic alcohols and ezetimibe lower serum cholesterol levels by two independent and unrelated mechanisms of action. Interestingly, when the mixture of higher primary aliphatic alcohols and ezetimibe combined showed a significant synergistic effect. The mixture of higher primary aliphatic alcohols inhibit a step located in between acetate consumption and mevalonate production whereas ezetimibe selectively inhibits intestinal cholesterol absorption thereby decreases

cholesterol available in the liver. Moreover, the mixture of higher primary aliphatic alcohols increase the number of LDL-C receptors in liver thereby reduces LDL-C levels. Both the compounds when used alone decrease TGs, VLDL, apoB, and increases HDL-C. Thus, the combination of both these agents into a single composition
5 provides a more effective treatment for elevated serum cholesterol than would be expected from the additive effect of both compounds given separately.

In an embodiment, the present invention provides pharmaceutical compositions suitable for lowering LDL-C and TGs level or elevating HDL-C level in blood of a mammal or both, by incorporating a combination of the mixture of high-molecular weight aliphatic
10 alcohols, and at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds; with ezetimibe, its salts, analogs or derivatives thereof into some suitable pharmaceutical forms such as tablets or capsules or both which may also comprise a pharmaceutically acceptable excipient(s) such as coloring agent, antioxidant, binder, stabilizer, and the
15 like.

The present invention provides process for preparation of a fixed dose combination comprising of the mixture of high-molecular weight aliphatic alcohols, and at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds; with ezetimibe, its salts, analogs or
20 derivatives thereof optionally with pharmaceutically acceptable excipients, which can be formulated as oral dosage forms such as tablets, pills, capsules, gels, finely divided powders, dispersions, suspensions, solutions, emulsions, etc; pulmonary and nasal dosage form such as sprays, aerosols, etc.; topical dosage forms such as gels, ointments, creams, etc; parenteral dosage forms; controlled release formulations; fast melt
25 formulations, lyophilized formulations, delayed release formulations, sustained release, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations. The compositions of the present invention can be formulated for administration by the route selected from the group consisting of oral, pulmonary, rectal, colonic, parenteral, local, buccal, nasal, and topical.

30 In an embodiment of the present invention, the compositions can be preferably incorporated into compositions in the form of capsules. These capsules may also

comprise pharmaceutically acceptable excipients such as diluent, antioxidant, coloring agent, stabilizer, and the like. Composition can also be provided in the form of tablets comprising combination of the mixture of high-molecular weight aliphatic alcohols, and at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds with ezetimibe, its salts, analogs or derivatives thereof which may also comprise excipients such as diluent, coloring agent, antioxidant, binder, stabilizer, and the like.

In an embodiment of the present invention, the composition as tablets/capsules or any other suitable pharmaceutical form are meant for lowering LDL-C level or elevating HDL-C level in mammals.

In an embodiment of the present invention, the ratio of the mixture of higher primary aliphatic alcohols or esters thereof and ezetimibe, its salts, analogs or derivatives thereof is from 20:1 to 1:20.

In a further embodiment, the composition comprising a combination of a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms comprising 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, and 1-triacontanol; phytosterols; resins and pigments; hydrocarbons; esters; ketones and aldehydes; and phenolic compounds with ezetimibe, its salts, analogs or derivatives thereof, optionally comprises pharmaceutically acceptable excipients.

In a further embodiment, the pharmaceutically acceptable excipients are selected from but not limited to a group comprising diluents, disintegrants, fillers, bulking agents, vehicles, pH adjusting agents, stabilizers, anti-oxidants, binders, buffers, lubricants, antiadherants, coating agents, preservatives, emulsifiers, suspending agents, release controlling agents, polymers, colorants, flavoring agents, plasticizers, solvents, preservatives, glidants, chelating agents and the like; used either alone or in combination thereof.

In the present invention, the diluent is selected from but not limited to a group comprising lactose, cellulose, microcrystalline cellulose, mannitol, dicalcium

phosphate, pregelatinized starch, and the like, used either alone or in combination thereof.

5 In the present invention, the binder is selected from but not limited to a group comprising polyvinylpyrrolidone, cellulose derivatives such as hydroxypropyl methylcellulose, methacrylic acid polymers, acrylic acid polymers, and the like.

The release controlling agents and/or polymers of the present invention comprising of at least one release controlling polymer is selected from but not limited to a group
10 comprising polyvinylpyrrolidone/polyvinylacetate copolymer (Kollidon® SR), methacrylic acid polymers, acrylic acid polymers, cellulose derivative, and the like. The methacrylic acid polymer is selected from a group comprising but not limited to Eudragit® (Degussa) such as Ammonio Methacrylate Copolymer type A USP (Eudragit® RL), Ammonio Methacrylate Copolymer type B USP (Eudragit® RS),
15 Eudragit® RSPO, Eudragit® RLPO, and Eudragit® RS30D.

In an embodiment, the lubricant(s) used in the present invention are selected from, but not limited to a group comprising of stearic acid, magnesium stearate, zinc stearate, glyceryl behenate, cetostearyl alcohol, hydrogenated vegetable oil, and the like used
20 either alone or in combination thereof.

In a further embodiment, the pharmaceutically acceptable excipients are present in about 0.5-80.0% by weight of the composition.

25 In a further embodiment, the present invention a process for preparing a composition according to claim 1 which comprises of the following steps:

- i) isolating the wax,
- ii) subjecting the wax to extraction with a liquid organic extractant in which primary aliphatic alcohols and other organic components are soluble,
- 30 iii) recovering said soluble mixture from said extractant,
- iv) purifying the extract by repeated washing and crystallization,
- v) drying the extract at temperature preferably below 70°C and making it into a powder form,

- vi) adding ezetimibe, its salts, analogs or derivatives,
- vii) optionally adding pharmaceutically acceptable excipients and making it into a suitable dosage form.

- 5 The wax is preferably isolated from a number of different sources, including sugar cane wax, beeswax, and rice bran wax, more preferably sugar cane wax.

The liquid organic extractant of the present invention are selected from but not limited to a group comprising hexane, heptane, petroleum ether, chlorinated hydrocarbons,
10 methanol, ethanol, isopropyl alcohol, ethyl acetate, acetone, ethyl methyl ketone, and the like, or mixtures thereof.

In the said process, the soluble mixture from the said extractant is recovered by distillation, with or without the application of vacuum.

15

The extract is purified preferably by repeated washing and crystallization. The solvents used for washing are selected from but not limited to hexane, heptane, petroleum ether, methanol, ethanol, isopropyl alcohol, ethyl acetate, acetone, ethyl methyl ketone, and the like, or mixtures thereof and the solvents for crystallization are selected from but
20 not limited to hexane, heptane, petroleum ether, chlorinated hydrocarbons, methanol, ethanol, isopropyl alcohol, ethyl acetate, acetone, ethyl methyl ketone, toluene, and the like, or mixtures thereof.

The extract is dried by subjecting it to hot air oven, or by a Fluid bed drier, preferably
25 at temperature below 70°C.

The present invention also provides a method of reducing serum cholesterol level, and treating hyperlipidemia, which comprises administering a composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to
30 99.9% by weight of the composition; at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition, and ezetimibe, its salts, analogs or derivatives thereof, substantially devoid of any waxy acid, optionally with

excipients from 0 to 99.9% by weight of the composition. The compositions of the present invention have preferably a synergistic effect for reducing serum cholesterol level, and treating hyperlipidemia, particularly in mammals.

5 The ability of the mixture of higher primary aliphatic alcohols to inhibit cholesterol synthesis and of ezetimibe, its salts, analogs or derivatives thereof to decrease total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), TGs, and lipoprotein (a) (Lp(a)) while increasing HDL-C; when combined in the present invention results in preferably a synergistic effect in lowering serum cholesterol.

10 In an embodiment, the compositions for lowering LDL-C level or elevating HDL-C level in blood of a mammal or both, comprise a mixture of higher primary aliphatic alcohols, and at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds; with ezetimibe, its salts, analogs or derivatives thereof, and a method for lowering LDL-C and/or TGs level or elevating HDL-C level in blood of a mammal or both, comprises
15 orally administering to said mammal, such compositions.

In an aspect of the present invention, the lipid lowering compositions comprising a mixture of higher primary aliphatic alcohols; at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds; and ezetimibe, its salts, analogs or derivatives thereof is
20 associated with a reduction in the dose of ezetimibe, its salts, analogs or derivatives thereof and increased patient compliance.

In the present invention, the mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; and other organic components such as resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds; is denoted as
25 'Extract-A'.

Determination of Biological activity

Casein-starch -induced hypercholesterolemia in rabbits

The observed unexpected synergistic lipid lowering effect of combination of Extract-A as described herein and ezetimibe is evidenced by the test conducted in rabbits. Rabbits of either sex were procured from Central Animal House facility; Panacea Biotech Ltd., India. Animals weighing 1.5-2.0 g at the time of testing were used throughout. All animals were dosed sequentially by the oral route with Extract-A and/or ezetimibe suspended in 0.5% of carboxymethyl cellulose (CMC). A dosing volume of 2 ml/kg was used for each sequential suspension.

The fasting serum lipid profile (TC, TGs, LDL-C, HDL-C) was estimated before initiation of the experiment. Total study duration was 90 days. Hypercholesterolemia was induced by feeding rabbits with wheat casein- starch diet (g/kg) containing wheat flour 333, cellulose 300, casein 270, water 20, maize oil 10, and mineral mixture (Kroon et al., 1982) for 8 weeks. Feed consumption was restricted to 100 g/day per animal. The cholesterol level was estimated every 15 days. After 60 days animals with total cholesterol level > 150 mg/dl were randomized to treatment (n = 6/group). Thereafter, various doses of Extract-A and/or ezetimibe were administered for another 60 days during which animals were fed with casein-starch diet. Blood samples were collected from fasted rabbits and analyzed for any alteration in serum lipid profile after 60 days of test compound(s) administration.

All the data are expressed as mean \pm S.E.M. (Standard Error of Mean). Student *t*-test was used to compare the lipid parameters between animals fed with standard and hypercholesterolemic diet. The difference between various drug treated groups was analyzed by ANOVA followed by Dunnett's test. A value of $P < 0.05$ was considered as statistically significant.

Rabbits fed with hypercholesterolemic diet for 60 days produced an increase in serum total cholesterol (TC) and LDL-C level in time dependent manner. Extract-A (100 and 200 mg/kg, p.o.) and ezetimibe (5 and 10 mg/kg, p.o.) reversed TC and LDL-C levels in comparison to hypercholesterolemic control rabbits. Lower doses of Extract-A (100

and 200 mg/kg) and ezetimibe (5 and 10 mg/kg) administered in combination, significantly potentiated the reduction in TC and LDL-C levels. There was no significant change in the body weight of casein-starch fed diet in comparison to initial body weight.

- 5 The data for the study is presented in Tables 1 & 2, and shown diagrammatically in Figures 1 & 2.

Table 1: Effect of Extract-A and/or ezetimibe on serum total cholesterol level in rabbits

Treatment	0	15	30	60	75	90	105	120
CNT	39.83 ± 2.79	119.83 ± 3.87	171.16 ± 7.88	231.83 ± 7.72	270 ± 6.55	290.00 ± 9.66	325.00 ± 8.07	350.00 ± 5.76
Extract-A 100	41.00 ± 2.3	102.166 ± 3.04	161.5 ± 6.42	227.6 ± 5.92	226.1 ± 6.19*	234.1 ± 7.23*	215.83 ± 10.37*	205.5 ± 15.3*
Extract-A 200	38.16 ± 2.5	101.0 ± 2.03	163.83 ± 11.84	227.83 ± 3.78	206.6 ± 5.34*	192.1 ± 3.08*	186.67 ± 4.99*	174.83 ± 4.39*
Ez-5	52.50 ± 3.59	103.50 ± 2.23	169.83 ± 6.16	219.83 ± 7.5	236.50 ± 3.47*	222.83 ± 2.77*	201.00 ± 12.6*	181.50 ± 8.55*
Ez-10	46.50 ± 2.2	106.83 ± 3.38	162.50 ± 11.54	234.50 ± 14.24	220.33 ± 8.73*	197.66 ± 5.42*	172.16 ± 6.58*	171.50 ± 4.7*
Extract-A 100 + Ez-5	49.5 ± 2.29	110.50 ± 5.21	146.00 ± 6.53	226.67 ± 11.33	175.83 ± 3.89 ^a	159.10 ± 3.41 ^a	129.66 ± 6.97 ^a	117.16 ± 4.7 ^a
Extract-A 200 + Ez-10	41.00 ± 2.3	102.16 ± 3.04	161.50 ± 6.42	212.16 ± 6.31	158.60 ± 5.85 ^a	135.83 ± 3.19 ^a	102.50 ± 1.9 ^a	75.33 ± 5.9 ^a

- 10 * $P < 0.05$ as compared with control (CNT); ^a $P < 0.05$ as compared with Extract-A 100 and 200 mg/kg, p.o., ezetimibe (Ez) 5 and 10 mg/kg, p.o.

Table 2: Effect of Extract-A and/or ezetimibe on LDL-C level in rabbits

Treatment	0	15	30	60	75	90	105	120
CNT	18.10 ± 1.53	67.60 ± 5.3	130.73 ± 7.08	193.23 ± 8.06	213.8 ± 7.6	242.93 ± 9.39	290.17 ± 7.64	325.73 ± 7.58
Extract-A 100	18.70 ± 3.32	78.23 ± 5.59	121.10 ± 7.54	184.67 ± 8.46	181.47 ± 6.8*	188.03 ± 7.46*	169.37 ± 7.71*	153.07 ± 8.62*
Extract-A 200	22.80 ± 5.4	76.30 ± 13.09	126.07 ± 3.31	186.9 ± 3.31	160.17 ± 3.79*	147.57 ± 3.86*	140.73 ± 6.3*	123.90 ± 4.09*
Ez-5	22.40 ± 8.81	76.13 ± 3.11	131.53 ± 6.89	174.3 ± 8.02	194.07 ± 4.29*	179.47 ± 3.74*	156.47 ± 12.92*	129.17 ± 9.02*
Ez-10	23.70 ± 7.98	72.70 ± 3.92	125.07 ± 10.94	197.03 ± 13.55	179.83 ± 9.83*	152.80 ± 6.17*	126.60 ± 6.85*	124.63 ± 6.55*

Extract-A	21.70 ± 5.45	77.00 ± 3.67	108.40 ± 5.7	182.9 ± 10.83	133.67 ± 4.33 ^a	112.17 ± 4.44 ^a	76.00 ± 7.12 ^a	66.37 ± 8.43 ^a
100+Ez-5								
Extract-A	24.87 ± 6.28	70.03 ± 4.55	119.63 ± 7.03	185.67 ± 10.45	117.23 ± 4.04 ^a	102.17 ± 6.71 ^a	73.63 ± 7.09 ^a	52.67 ± 9.95 ^a
200+Ez-10								

* $P < 0.05$ as compared with control (CNT); ^a $P < 0.05$ as compared with Extract-A (100 and 200 mg/kg, p.o.), ezetimibe (Ez) (5 and 10 mg/kg, p.o).

Description of Figures:

- 5 Figure 1: Effect of Extract-A and/or ezetimibe on serum total cholesterol level in rabbits

Figure 2: Effect of Extract-A and/or ezetimibe on LDL-C level in rabbits

- The examples given below serve to illustrate embodiments of the present invention.
 10 However they do not intend to limit the scope of present invention.

EXAMPLES

Preparation of extract

Example 1

- 15 4 kg of air-dried Sugar mill Filter cake (or Press Mud) obtained as a byproduct during sugar manufacture from sugarcane was pulverized and extracted four times by boiling with 20 L of dichloroethane each time. The dichloroethane extract was filtered and the solvent was distilled off to get a dark green residue (400 g). The residue was extracted with 4 L of boiling methanol 3 times and the extract was filtered to remove the pitch
 20 while still hot (temperature above 50°C). The filtered extract was distilled to remove methanol till a green residue (200 g) is obtained. The residue was dissolved in 2 L of boiling ethyl methyl ketone and set aside for crystallization. After complete crystallization the solvent is filtered, concentrated to half its volume by distillation and set aside for crystallization of the second crop. Both the crops were pooled and washed
 25 with cold hexane. The crystallization and washing procedures were repeated once more. The final washed crystals were dried under a current of air at a temperature not

exceeding 70°C. The resultant creamish yellow lumps were pulverized to a fine powder (50 g).

Example 2

5 Beeswax obtained after extraction of honey from honeycomb was dried and pulverized and extracted four times by boiling with of ethyl alcohol each time. The alcoholic extract was filtered and the solvent was distilled off to get a residue. The residue was extracted with boiling methanol 3 times and the extract was filtered to remove the pitch while still hot (temperature above 50°C). The filtered extract was distilled to remove
10 methanol till a green residue is obtained. The residue was dissolved in boiling ethyl acetate and set aside for crystallization. After complete crystallization the solvent is filtered, concentrated to half its volume by distillation and set aside for crystallization of the second crop. Both the crops were pooled and washed with cold hexane. The crystallization and washing procedures were repeated once more. The final washed
15 crystals were dried under a current of air at a temperature not exceeding 70°C. The resultant lumps were pulverized to a fine powder.

Example 3

4 kg of air-dried Sugar mill Filter cake (or Press Mud) was pulverized and extracted
20 four times by boiling with 20 L of hexane each time. The hexane extract was filtered and the solvent was distilled off to get a dark green residue (350 g). The residue was extracted with 3.5 L of boiling methanol 3 times and the extract was filtered to remove the pitch while still hot (temperature above 50°C). The filtered extract was distilled to remove methanol till a green residue (200 g) is obtained. The residue was dissolved in 2
25 L of boiling acetone and set aside for crystallization. After complete crystallization the solvent is filtered, concentrated to half its volume by distillation and set aside for crystallization of the second crop. Both the crops were pooled and washed with cold hexane. The crystallization and washing procedures were repeated once more. The final washed crystals were dried under a current of air at a temperature not exceeding 70°C.
30 The resultant creamish yellow lumps were pulverized to a fine powder (45 g).

Example 4

10 kg of air-dried Sugar mill Filter cake (or Press Mud) was pulverized and extracted four times by boiling with 50 L of methanol each time. The methanol extract was filtered and the solvent was distilled off to get a dark green residue (650 g). The residue
5 was extracted with 6.5 L of boiling methanol 3 times and the extract was filtered to remove the pitch while still hot (temperature above 50°C). The filtered extract was distilled to remove methanol till a green residue (500 g) is obtained. The residue was dissolved in 2 L of boiling ethyl acetate and set aside for crystallization. After complete crystallization the solvent is filtered, concentrated to half its volume by distillation and
10 set aside for crystallization of the second crop. Both the crops were pooled and washed with cold hexane. The crystallization and washing procedures were repeated once more. The final washed crystals were dried under a current of air at a temperature not exceeding 70°C. The resultant creamish yellow lumps were pulverized to a fine powder (102 g).

15

Preparation of compositions**Example 5 (Capsule)**

Ingredient	mg/capsule
Extract-A	80.0
20 Ezetimibe	5.0
Microcrystalline cellulose	200.8
Mannitol	72.0
Talc	3.2
Sodium starch glycollate	12.0
25 Colloidal silicon dioxide	12.0

Procedure:

- 1) Extract-A, ezetimibe, microcrystalline cellulose and mannitol are sifted and mixed together.
- 30 2) Talc, sodium starch glycollate and colloidal silicon dioxide are passed through fine sieves individually and then mixed together.
- 3) The materials of step 1 and 2 are mixed and filled into empty hard gelatin capsules

Example 6 (Uncoated tablet)

	Ingredient	mg/tablet
	Extract-A	80.0
5	Ezetimibe	10.0
	Microcrystalline cellulose	120.0
	Mannitol	80.0
	Croscarmellose sodium	10.0
	Lactose	66.0
10	Talc	4.0
	Colloidal silicon dioxide	10.0
	Croscarmellose sodium	10.0

Procedure:

- 15 1) Extract-A, ezetimibe, microcrystalline cellulose, mannitol, croscarmellose sodium and lactose are sifted and mixed together.
- 2) The material of step 1 is compacted.
- 3) The compacts of step 2 are passed through sieve and mixed.
- 4) Talc, colloidal silicon dioxide and croscarmellose sodium are passed through
- 20 fine sieve and mixed together.
- 5) The material of step 3 is mixed with material of step 4.
- 6) The material of step 5 is compressed into tablets.

Example 7 (Film-coated tablet)

25	Ingredient	mg/tablet
	<u>Core tablet composition</u>	
	Extract-A	40.0
	Ezetimibe	10.0
	Microcrystalline cellulose	120.0
30	Mannitol	80.0
	Croscarmellose sodium	10.0
	Lactose	66.0
	Talc	4.0
	Colloidal silicon dioxide	10.0

Croscarmellose sodium	10.0
-----------------------	------

Film coating composition

	Hydroxypropyl methylcellulose (E-15)	12.0
5	Polyethylene glycol 400 (PEG 400)	2.4
	Iron oxide red	0.75
	Iron oxide yellow	0.50
	Titanium dioxide	0.25
	Isopropyl alcohol	q.s. (lost in processing)
10	Dichloromethane	q.s. (lost in processing)

Procedure:

- 1) Extract-A, ezetimibe, microcrystalline cellulose, mannitol, croscarmellose sodium and lactose are sifted and mixed together.
- 15 2) The material of step 1 is compacted.
- 3) The compacts of step 2 are passed through sieve and mixed.
- 4) Talc, colloidal silicon dioxide and croscarmellose sodium are passed through fine sieve and mixed together.
- 5) The material of step 3 is mixed with material of step 4.
- 20 6) The material of step 5 is compressed into tablets.
- 7) Hydroxypropyl methylcellulose is dispersed in a mixture of isopropyl alcohol and dichloromethane with continuous mixing in homogenizer.
- 8) PEG 400 is added to the above solution of step 7 and mixed.
- 9) Iron oxide red, iron oxide yellow and titanium dioxide are passed through fine
- 25 sieve and mixed.
- 10) The material of step 9 is added to material of step 8 and mixed for 30 minutes.
- 11) The core tablets are charged into the coating pan and coated with the coating solution of step 10 till an average tablet weight gain of ~2-3% is achieved.

CLAIMS


1. A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to 99.9% by weight of the composition; at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition, and ezetimibe, its salts, analogs or derivatives thereof substantially devoid of any waxy acid, optionally with pharmaceutically acceptable excipients from 0 to 99.9% by weight of the composition.
2. A composition according to claim 1, wherein the mixture of higher primary aliphatic alcohols comprises 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, and 1-triacontanol.
3. A composition according to claims 1 and 2, wherein the mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms comprising 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, and 1-triacontanol are present as at least 40% by weight of the composition.
4. A composition according to claims 1-3, wherein the ratio of the mixture of higher primary aliphatic alcohols and ezetimibe, its salts, analogs or derivatives thereof is from 20:1 to 1:20.
5. A composition according to claims 1-5 wherein the pharmaceutically acceptable excipients are selected from a group comprising diluents, disintegrants, fillers, bulking agents, vehicles, pH adjusting agents, stabilizers, anti-oxidants, binders, buffers, lubricants, antiadherants, coating agents, preservatives, emulsifiers, suspending agents, release controlling agents, polymers, colorants, flavoring agents, plasticizers, solvents, preservatives, glidants, chelating agents and the like; used either alone or in combination thereof.
6. A pharmaceutical composition according to claims 1-5, which is formulated as oral dosage forms such as tablets, pills, capsules, gels, finely divided powders, dispersions, suspensions, solutions, emulsions, etc; pulmonary and nasal dosage form such as sprays, aerosols, etc.; topical dosage forms such as gels, ointments, creams, etc; parenteral dosage forms; controlled release formulations; fast melt

formulations, lyophilized formulations, delayed release formulations, sustained release, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.

- 5 7. A process for preparing a pharmaceutical composition according to claim 1 which comprises of the following steps:
- i) isolating the wax,
 - ii) subjecting the wax to extraction with a liquid organic extractant in which primary aliphatic alcohols and other organic components are soluble,
 - 10 iii) recovering said soluble mixture from said extractant,
 - iv) purifying the extract by repeated washing and crystallization,
 - v) drying the extract and making it into a powder form,
 - vi) adding ezetimibe, its salts, analogs or derivatives,
 - 15 vii) optionally adding pharmaceutically acceptable excipients and making it into a suitable dosage form.
8. A process according to claim 7, wherein the mixture of higher primary aliphatic alcohols comprises 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, and 1-triacontanol.
- 20 9. A process according to claims 7 and 8, wherein the mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms comprising 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-octacosanol, and 1-triacontanol are present as at least 40% by weight of the composition.
- 25 10. A process according to claims 7-9, wherein the ratio of the mixture of higher primary aliphatic alcohols and ezetimibe, its salts, analogs or derivatives thereof is from 20:1 to 1:20.
11. A method of reducing serum cholesterol level, and treating hyperlipidemia, which comprises administering a composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to 99.9% by weight of the composition; at least one another organic component selected

- from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition, and ezetimibe, its salts, analogs or derivatives thereof, substantially devoid of any waxy acid, optionally with pharmaceutically acceptable excipients from 0 to 99.9% by weight of the composition.
- 5
12. Use of a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to 99.9% by weight of the composition; at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition, and ezetimibe, its salts, analogs or derivatives thereof, substantially devoid of any waxy acid, for preparing a composition for reducing serum cholesterol level, and treating hyperlipidemia.
- 10
13. A composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to 99.9% by weight of the composition; at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition, and ezetimibe, its salts, analogs or derivatives thereof, substantially devoid of any waxy acid, as herein described and illustrated by the examples.
- 15
14. The process for the preparation of a composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms from 2 to 99.9% by weight of the composition; at least one another organic component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds from 0.1 to 70% by weight of the composition, and ezetimibe, its salts, analogs or derivatives thereof, substantially devoid of any waxy acid, as herein described and illustrated by the examples.
- 20
- 25

Figure 1:




5

*P<0.05 as compared with control (CNT); ^aP<0.05 as compared with Extract-A 100 and 200 mg/kg, p.o., ezetimibe (Ez) 5 and 10 mg/kg, p.o.

10

Figure 2:



5

10 *P<0.05 as compared with control (CNT); ^aP<0.05 as compared with Extract-A 100 and 200 mg/kg, p.o., ezetimibe (Ez) 5 and 10 mg/kg, p.o.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/IN2005/000025

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/045 A61K31/397 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data, SCISEARCH, PASCAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/103632 A (ELAN PHARMA INTERNATIONAL, LTD; COOPER, EUGENE, R; KLINE, LAURA, J; LI) 18 December 2003 (2003-12-18) claims 39,95,100 -----	1-6, 11-13
X	US 6 225 354 B1 (PEREZ PEDRO P) 1 May 2001 (2001-05-01) claims 1,8-6 -----	7-10,14
A	BAYS H ET AL: "PHARMACOTHERAPY FOR DYSLIPIDAEMIA - CURRENT THERAPIES AND FUTURE AGENTS" EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON,, GB, vol. 4, no. 11, 2003, pages 1901-1938, XP008027524 ISSN: 1465-6566 page 1907 - page 1908 page 1913 -----	1-14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

2 May 2005

Date of mailing of the international search report

17/05/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Zimmer, B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IN2005/000025

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 11 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Inter:
 Application No
 PCT/IN2005/000025

Patent document cited in search report		Publication date	Patent family member(s)			Publication date
WO 03103632	A	18-12-2003	AU	2003241477	A1	22-12-2003
			CA	2488498	A1	18-12-2003
			EP	1511467	A1	09-03-2005
			WO	03103632	A1	18-12-2003
			US	2003232796	A1	18-12-2003
<hr/>						
US 6225354	B1	01-05-2001	AU	6404600	A	09-01-2001
			CA	2375396	A1	28-12-2000
			EP	1189605	A2	27-03-2002
			JP	2003502396	T	21-01-2003
			NZ	516386	A	29-04-2005
			WO	0078697	A2	28-12-2000
			US	2003096876	A1	22-05-2003
			US	2004019119	A1	29-01-2004
			US	2002058713	A1	16-05-2002
US	2002099099	A1	25-07-2002			
<hr/>						